Evidence map›Paper›PMID 23200980›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2013

Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia.

Mitsuro Kanda, Yoshihiko Sadakari, Michael Borges, Mark Topazian, James Farrell, Sapna Syngal, Jeffrey Lee, Ihab Kamel, Anne Marie Lennon, Spencer Knight and 4 more

3 registry-linked trialsOpen access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00438906 completednot on this map

Screening for Early Pancreatic Neoplasia

TypeobservationalSponsorJohns Hopkins UniversityRan2006 to 2009Enrolled200ConditionsPancreatic Neoplasm, Peutz-Jeghers SyndromeArmsBiopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
NCT00714701 completednot on this map

Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)

TypeobservationalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2008 to 2016Enrolled631ConditionsEarly Pancreatic Neoplasia, Familial Pancreatic Neoplasia
NCT03820531 nacompletednot on this mapstarted 2018, after this paper: background citation

DNA-mutation Analysis by Next Generation Sequencing in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas Obtained by Endoscopic Ultrasound-guided Fine Needle Aspiration (ZYSTEUS-Study)

TypeinterventionalSponsorTheresienkrankenhaus und St. Hedwig-Klinik GmbHRan2018 to 2022Enrolled150ConditionsPancreas CystArmsNext Generation Sequencing, CEA and lipase, Cytology, Histology of resected pancreas cyst
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. New avenues for the treatment of immunotherapy-resistant pancreatic cancer.World journal of gastrointestinal oncology · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Mitsuro KandaDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Yoshihiko Sadakari
Michael Borges
Mark Topazian
James Farrell
Sapna Syngal
Jeffrey Lee
Ihab Kamel
Anne Marie Lennon
Spencer Knight
Sho Fujiwara
Ralph H Hruban
Marcia Irene Canto
Michael Goggins
Cancer Research Center · USJohns Hopkins University · USDana-Farber Cancer Institute · USMayo Clinic · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI KERN, SCOTT E · 1993 to 2022
$54.6M
Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trialRC2CA148346 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2009 to 2010
$1.9M
The Genetics and Prevention of Gastrointestinal CancersK24CA113433 · NCI · DANA-FARBER CANCER INSTITUTE · PI SYNGAL, SAPNA · 2005 to 2014
$1.7M
Markers of Early Pancreatic CancerR01CA120432 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2006 to 2010
$1.4M
NCI NIH HHS CA62924NCI NIH HHS K24 CA113433NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA120432NCI NIH HHS R01CA120432NCI NIH HHS RC2 CA148346NCI NIH HHS RC2CA148376
6 · The paper itself

Abstract

BACKGROUND &

aimsImaging tests can identify patients with pancreatic neoplastic cysts but not microscopic dysplasia. We investigated whether mutant TP53 can be detected in duodenal samples of secretin-stimulated pancreatic juice, and whether this assay can be used to screen for high-grade dysplasia and invasive pancreatic cancer.

methodsWe determined the prevalence of mutant TP53 in microdissected pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and invasive adenocarcinomas. TP53 mutations were quantified by digital high-resolution melt-curve analysis and sequencing of secretin-stimulated pancreatic juice samples, collected from duodena of 180 subjects enrolled in Cancer of the Pancreas Screening trials; patients were enrolled because of familial and/or inherited predisposition to pancreatic cancer, or as controls.

resultsTP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs. TP53 mutations were detected in duodenal samples of pancreatic juice from 29 of 43 patients with pancreatic ductal adenocarcinoma (67.4% sensitivity; 95% confidence interval, 0.52-0.80) and 4 of 8 patients with high-grade lesions (PanIN-3 and high-grade IPMN). No TP53 mutations were identified in samples from 58 controls or 55 screened individuals without evidence of advanced lesions.

conclusionsWe detected mutant TP53 in secretin-stimulated pancreatic juice samples collected from duodena of patients with high-grade dysplasia or invasive pancreatic cancer. Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and high-grade dysplasia. Clinical Trial numbers: NCT00438906 and NCT00714701.

Indexed as

AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutant ProteinsPancreatic JuicePancreatic NeoplasmsPrecancerous ConditionsTumor Suppressor Protein p53Mutant ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID23200980
PMCPMC3600161
OpenAlexW2149894487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.